Company / Free Cash Flow per Share
Janux Therapeutics, Inc. Free Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$1.34
FY2025
5-year range
-$1.34 / -$0.78
FY2021-FY2025
Trend
-63.5%
vs FY2024
Sector context
#113 of 190
Health Care
What the data says
At $-1.34, Janux Therapeutics, Inc.'s free cash flow per share ranks #113 of 190 in the Health Care sector. Free Cash Flow per Share has fluctuated over the past 6 years, ranging from $-4.77 in FY2020 to $-0.78 in FY2021.
Based on SEC 10-K filings.
-1.34 in FY2025.
Declined from $-1.19 to $-1.34 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#113 of 190 in Health CareTop 59% of 190This company -$1.34 Sector average $3.32
▼
-140.4% below sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 63.5% year-over-year.
- Ranks #113 out of 190 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2021.
- Lowest free cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.34 | -63.5% |
| FY2024 | -$0.82 | +31.0% |
| FY2023 | -$1.19 | -0.1% |
| FY2022 | -$1.19 | -51.8% |
| FY2021 | -$0.78 | +83.6% |
| FY2020 | -$4.77 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026